Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP9 | P55211 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613460 | 0.85 | CA12 (0.37) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL970504 | 0.73 | AHR (0.48) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL5420509 | 0.73 | — | — | |
| SCHEMBL89023 | 0.71 | ALOX15 (0.56) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL130192 | 0.70 | — | — | |
| SCHEMBL630416 | 0.69 | CA12 (0.48) | CA12CA9 | |
| SCHEMBL8811788 | 0.69 | CYP2A6 (0.52) | CYP1A2 | |
| SCHEMBL1828552 | 0.67 | — | — | |
| SCHEMBL319460 | 0.67 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL11198759 | 0.67 | PDE3B (0.36) | CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648245-A | Tetrahydroquinoline derivative and medical application thereof | 东丽株式会社 | 2023-08-25 | — | — | CN | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | AIFM2, TXNRD2, NFE2L2 | AHR 2101/4885PDK2 574/4885TDP2 3600/4885 |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | AHR 313/4885PDK2 3088/4885TDP2 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.